Bilayer-functionalized mesoporous silica nanoparticles for overcoming multiple barriers of mucus clearance, intestinal epithelium and P-glycoprotein efflux
Source abstract
Abstract
Mucus clearance, epithelium mucosal barrier and P-glycoprotein (P-gp) efflux are the main gastrointestinal barriers that limit the oral delivery of nanoparticles. Inspired by tunable particles surface properties-dependent trans-mucus and trans-mucosal abilities, novel bilayer-functionalized mesoporous silica nanoparticles (MSN) containing D-α-tocopheryl polyethylene glycol succinate (TPGS) and sulfobetaine 12 (SB12) were designed by layer-to-layer assembly. The amino-grafted MSN (MSN-NH2) was firstly functionalized with TPGS as hydrophobic layer (MSN-TPGS), and then SB12 was self-assembled on the hydrophobic surface of MSN-TPGS to generate a neutral and hydrophilic MSN (MSN-TPGS@SB12). Compared with MSN-NH2, MSN-TPGS, and MSN-TPGS@P123, the MSN-TPGS@SB12 possessed “one stone three birds” functions that enhanced mucus penetration, increased trans-mucosal absorption, as well as suppressed P-gp efflux. The pharmacokinetics study demonstrated that the MSN-TPGS@SB12 loading puerarin (MSN-TPGS@SB12-PUE) exhibited much higher bioavailability compared to other PUE-loaded formulations. Furthermore, the MSN-TPGS@SB12-PUE could significantly enhance the anti-inflammatory efficacy of PUE in vitro and in vivo. In summary, bilayer-functionalized MSN-TPGS@SB12 is a promising vehicle for overcoming the multiple gastrointestinal barriers (mucus clearance, intestinal epithelium barrier and P-gp efflux). Meanwhile, this study also provides a better understanding of the importance of tunable surface property of MSN on oral delivery of drug.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Advanced Drug Delivery Systems · Nanoparticle-Based Drug Delivery · Drug Solubulity and Delivery Systems
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (50)
Show source-provided references
1. Nanoparticles for oral delivery: design, evaluation and state-of-the-art10.1016/j.jconrel.2016.06.016 ↗
2. Navigating the human gastrointestinal tract for oral drug delivery: uncharted waters and new frontiers10.1016/j.addr.2016.03.009 ↗
3. Nanoparticles for oral delivery: targeted nanoparticles with peptidic ligands for oral protein delivery10.1016/j.addr.2012.10.007 ↗
4. Advances in the transepithelial transport of nanoparticles10.1016/j.drudis.2016.05.007 ↗
5. Mechanisms of nanoparticle transport across intestinal tissue: an Oral delivery perspective10.1021/acsnano.3c02403 ↗
6. Bioinert, stealth or interactive: how surface chemistry of nanocarriers determines their fate in vivo10.1002/adfm.202103347 ↗
7. Challenges associated with penetration of nanoparticles across cell and tissue barriers: a review of current status and future prospects10.1016/j.nantod.2014.04.008 ↗
8. Engineering nanoparticles to overcome the mucus barrier for drug delivery: design, evaluation and state-of-the-art10.1016/j.medidd.2021.100110 ↗
9. The Nano-intestine interaction: understanding the location-oriented effects of engineered nanomaterials in the intestine10.1002/smll.201907665 ↗
10. PEGylation for enhancing nanoparticle diffusion in mucus10.1016/j.addr.2017.08.010 ↗
11. V.V. Khutoryanskiy, beyond pegylation: alternative surface-modification of nanoparticles with mucus-inert biomaterials beyond pegylation: alternative surface-modification of nanoparticles with mucus-inert biomaterials. 124 (2018) 140-149.10.1016/j.addr.2017.07.015 ↗
12. Polydopamine coating enhances mucopenetration and cell uptake of nanoparticles10.1021/acsami.8b18107 ↗
13. Zwitterionic polydopamine modified nanoparticles as an efficient nanoplatform to overcome both the mucus and epithelial barriers10.1016/j.cej.2021.132107 ↗
14. Enhanced Oral delivery of protein drugs using zwitterion-functionalized nanoparticles to overcome both the diffusion and absorption barriers10.1021/acsami.6b08183 ↗
15. Nanoparticles exhibiting virus-mimic surface topology for enhanced oral delivery10.1038/s41467-023-43465-y ↗
16. Mucus penetrating and cell-binding polyzwitterionic micelles as potent Oral nanomedicine for cancer drug delivery10.1002/adma.202109189 ↗
17. Zwitterionic biomaterials10.1021/acs.chemrev.2c00344 ↗
18. Zwitterion-functionalized mesoporous silica nanoparticles for enhancing oral delivery of protein drugs by overcoming multiple gastrointestinal barriers10.1016/j.jcis.2020.08.010 ↗
19. Enhanced Oral delivery of protein drugs using zwitterion-functionalized nanoparticles to overcome both the diffusion and absorption barriers10.1021/acsami.6b08183 ↗
20. Biological fate and interaction with cytochromes P450 of the nanocarrier material, D-α-tocopheryl polyethylene glycol 1000 succinate10.1016/j.apsb.2022.01.014 ↗
21. Vitamin E TPGS as a molecular biomaterial for drug delivery10.1016/j.biomaterials.2012.03.046 ↗
22. Vitamin E TPGS-based nanomedicine, nanotheranostics, and targeted drug delivery: past, present, and future10.3390/pharmaceutics15030722 ↗
23. Recent advances in the application of vitamin E TPGS for drug delivery10.7150/thno.22711 ↗
24. Recent developments in d-α-tocopheryl polyethylene glycol-succinate-based nanomedicine for cancer therapy10.1080/10717544.2017.1406561 ↗
25. Enhanced oral paclitaxel absorption with vitamin E-TPGS: effect on solubility and permeability in vitro, in situ and in vivo10.1016/j.ejps.2005.04.003 ↗
26. Dendritic mesoporous nanoparticles: structure, synthesis and properties10.1002/anie.202112752 ↗
27. Mesoporous silica nanoparticles-based nanoplatforms: basic construction, current state, and emerging applications in anticancer therapeutics10.1002/adhm.202201884 ↗
28. Mesoporous silica nanoparticles with chiral pattern topological structure function as “antiskid tires” on the intestinal mucosa to facilitate oral drugs delivery
29. Pharmacokinetics and drug delivery systems for puerarin, a bioactive flavone from traditional chinese medicine10.1080/10717544.2019.1660732 ↗
30. Alteration of UDP-glucuronosyltransferase 1a1, 1a7 and P-glycoprotein expression in hepatic fibrosis rats and the impact on pharmacokinetics of puerarin10.1016/j.phymed.2018.06.024 ↗
31. Mucus interaction to improve gastrointestinal retention and pharmacokinetics of orally administered nano-drug delivery systems10.1186/s12951-022-01539-x ↗
32. Enhancement of dissolution and oral bioavailability of lacidipine via pluronic P123/F127 mixed polymeric micelles: formulation, optimization using central composite design and in vivo bioavailability study10.1080/10717544.2017.1419512 ↗
33. Anion assisted synthesis of large pore hollow dendritic mesoporous organosilica nanoparticles: understanding the composition gradient10.1021/acs.chemmater.5b03963 ↗
34. Mucus-penetrating dendritic mesoporous silica nanoparticle loading drug nanocrystal clusters to enhance permeation and intestinal absorption10.1039/D2BM01404A ↗
35. LC-MS/MS determination and pharmacokinetics study of puerarin and daidzein in rat plasma after oral administration of gegenqinlian decoction and radix puerariae extract10.4103/0973-1296.137363 ↗
36. Mucins in the gastrointestinal tract in health and disease10.2741/Corfield ↗
37. The properties of the mucus barrier, a unique gel - how can nanoparticles cross it10.4155/tde-2015-0002 ↗
38. Advances in Oral drug delivery systems: challenges and opportunities10.3390/pharmaceutics15020484 ↗
39. Barrier properties of mucus10.1016/j.addr.2008.09.008 ↗
40. Developments of mucus penetrating nanoparticles10.1016/j.ajps.2014.12.007 ↗
41. Engineering nanomaterials to overcome the mucosal barrier by modulating surface properties10.1016/j.addr.2017.10.001 ↗
42. To enhance mucus penetration and lung absorption of drug by inhalable nanocrystals-in-microparticles10.3390/pharmaceutics14030538 ↗
43. Mucus penetration of surface-engineered nanoparticles in various pH microenvironments10.1021/acsnano.2c11147 ↗
44. In vivo study of the mucus-permeating properties of PEG-coated nanoparticles following oral administration10.1016/j.ejpb.2014.12.021 ↗
45. Surface design of nanocarriers: key to more efficient oral drug delivery systems
46. Vitamin E TPGS modified liposomes enhance cellular uptake and targeted delivery of luteolin: an in vivo/in vitro evaluation10.1016/j.ijpharm.2016.08.037 ↗
47. Virus-mimicking mesoporous silica nanoparticles with an electrically neutral and hydrophilic surface to improve the Oral absorption of insulin by breaking through dual barriers of the mucus layer and the intestinal epithelium10.1021/acsami.1c00580 ↗
48. P-glycoprotein mediated interactions between chinese materia medica and pharmaceutical drugs10.1016/j.dcmed.2021.12.001 ↗
49. Synergistic effects of multidrug/material combination deliver system for anti-mutidrug-resistant tumor10.1016/j.ijpharm.2023.123669 ↗
50. Effect of surface functionalization and pore structure type on the release performance of mesoporous silica nanoparticles10.1016/j.micromeso.2022.111862 ↗